Table 14.

Enriched KEGG pathways derived by genes corresponding to CpG sites selected by GoRevenge-based selection (a) and genes corresponding to CpG sites selected by evolutionary selection (b). (a) Using GoRevenge results; and (b) using evolutionary selection results.

	Pathway ID	Pathway Description	p-Value	Enrichment
(a)
1	hsa05205	Proteoglycans in cancer	1.37 × 10−12	24/222
2	hsa05215	Prostate cancer	2.58 × 10−12	17/88
3	hsa04390	Hippo signaling pathway	5.86 × 10−12	20/154
4	hsa04910	Insulin signaling pathway	9.91 × 10−12	20/136
5	hsa05200	Pathways in cancer	2.39 × 10−11	44/326
6	hsa05166	HTLV-I infection	3.52 × 10−11	25/263
7	hsa04020	Calcium signaling pathway	4.52 × 10−11	25/181
8	hsa04916	Melanogenesis	5.73 × 10−11	15/99
9	hsa04010	MAPK signaling pathway	6.98 × 10−11	27/257
10	hsa04722	Neurotrophin signaling pathway	1.18 × 10−10	16/118
11	hsa04151	PI3K-Akt signaling pathway	1.22 × 10−10	27/341
12	hsa04310	Wnt signaling pathway	2.82 × 10−10	17/143
13	hsa05217	Basal cell carcinoma	3.93 × 10−10	11/55
14	hsa04510	Focal adhesion	3.97 × 10−10	20/204
15	hsa04350	TGF-beta signaling pathway	4.18 × 10−10	13/81
16	hsa05202	Transcriptional misregulation in cancer	4.78 × 10−10	18/165
17	hsa00053	Ascorbate and aldarate metabolism	7.52 × 10−10	8/26
18	hsa05030	Cocaine addiction	2.11 × 10−9	10/50
19	hsa00500	Starch and sucrose metabolism	3.30 × 10−9	10/52
(b)
1	hsa04260	Cardiac muscle contraction	9.81 × 10−5	6/76
2	hsa04974	Protein digestion and absorption	2.29 × 10−4	6/87
3	hsa05410	Hypertrophic cardiomyopathy (HCM)	1.28 × 10−3	5/85
4	hsa05414	Dilated cardiomyopathy	1.72 × 10−3	5/90
5	hsa00061	Fatty acid biosynthesis	2.86 × 10−3	1/6
6	hsa05412	Arrhythmogenic right ventricular cardiomyopathy (ARVC)	3.70 × 10−3	4/73
7	hsa00460	Cyanoamino acid metabolism	3.97 × 10−3	1/7
8	hsa04961	Endocrine and other factor-regulated calcium reabsorption	4.98 × 10−3	3/49
9	hsa05030	Cocaine addiction	5.36 × 10−3	3/50
10	hsa04512	ECM-receptor interaction	7.41 × 10−3	4/86
11	hsa04730	Long-term depression	0.010	3/60